NeuroDigm's Model Reveals the Reversal of Chronic Pain.Chronic Pain Patients Need an Answer to the Question, "Why Hasn't My Pain Healed?" NeuroDigm Has Found That Epoetin Alpha, a Recombinant Human Erythropoietin erythropoietin /eryth·ro·poi·e·tin/ (-poi´e-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production , Can Heal the Nerves Causing Pain in a Research Model and Also in Pain Patients. This Translational Research Suggests That Many Chronic Pain Conditions Are Related to Neural Regeneration, Not Neuronal Death as Commonly Thought. FT. WORTH, Texas -- Mary Hannaman MD, president of NeuroDigm Co. in Fort Worth, Texas Fort Worth is the fifth-largest city in the state of Texas, 18th-largest city in the United States[1], and voted one of "America’s Most Livable Communities. has confirmed that a recombinant human erythropoietin, epoetin alfa e·po·e·tin al·fa n. A recombinant preparation of human erythropoietin used to treat some forms of anemia. epoetin alfa Epogen, Eprex (CA) (UK), Procrit Pharmacologic class: , can reverse neural changes that cause chronic pain behavior pain behavior, n a joint test during which the patient indicates a particular point in which pain is initially experienced and/or increases while the practitioner moves the joint through the range of motion. . Using their Biogenic biogenic /bi·o·gen·ic/ (-jen´ik) having origins in biological processes. biogenic having the property of originating in a biological process. Model of Chronic Pain[TM], epoetin alpha was applied once locally in micro doses to the affected nerves resulting in the reversal of pain behaviors permanently. Many types of chronic pain are resistant to treatments, needing opiates Opiates Analgesic, pain killing drugs, such as heroin and morphine that depress the central nervous system. Mentioned in: Withdrawal Syndromes , oral drugs, anesthetic blocks, and spinal pumps or spinal stimulators to control the pain. Some may even have the identified nerve cut to attempt to relieve pain. Dr. Hannaman says that NeuroDigm's animal model can transform the future for chronic pain patients by predicting the realistic clinical efficacy of drugs and biopharmaceuticals and enable more targeted treatments with less side effects. NeuroDigm has developed their model to give the biotechnology, pharmaceutical and research industries a more realistic model by correlating the development of the model with the process of human tissue repair. Dr. Hannaman says many chronic pain conditions develop gradually after an injury as the tissue repairs itself and have no evidence of nerve damage. The animal studies are supported by Dr. Hannaman's clinical experience with chronic pain patients. After identifying the specific nerve involved in a patient's pain, a single application percutaneously of very small doses of epoetin alpha to an identified site of neural inflammation can rapidly and permanently reverse the associated pain behavior including mechanical allodynia. Localized treatments have been performed with epoetin alpha in patients on many peripheral nerves including the sciatic nerve, lateral femoral femoral /fem·o·ral/ (fem´or-al) pertaining to the femur or to the thigh. fem·o·ral adj. Of or relating to the femur or thigh. cutaneous nerve and spinal accessory nerves the eleventh pair of cranial nerves in the higher vertebrates. They originate from the spinal cord and pass forward into the skull, from which they emerge in company with the pneumogastrics. See also: Spinal . NeuroDigm is a private R&D company in Fort Worth, Texas. NeuroDigm licenses proprietary models (US Patent 7015371) to enable the development of more effective treatments for chronic nerve pain. Medical devices to help in the clinical diagnosis of chronic pain are also being developed. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion